Drugs / AS-Probionorm
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06252831 | Sep → Oct 2023 | colonic disorder, intestinal infectious disease | Industrial Microbiology LLP | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06886399 | Jul → Aug 2024 | intestinal infectious disease | Industrial Microbiology LLP | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AS-Probionorm | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06886399 ↗ |
| Modality | Other / unclassified | “investigational probiotic medicine” NCT06252831 ↗ |
| Route | Oral | “for oral use” NCT06252831 ↗ |